Unadjusted Relative Hazards of Liver Disease Progression Events for Baseline Covariates
| Variable . | Unadjusted HR (95% CI) . |
|---|---|
| Age >45 vs ≤45 years | 1.57 (0.68, 3.59) |
| Male vs female | 2.33 (0.80, 6.84) |
| Race/Ethnicity | |
| Black non-Hispanic | 1.57 (0.51, 4.82) |
| Hispanic | 1.62 (0.47, 5.54) |
| White non-Hispanic | Referent |
| History of diabetes | 1.52 (0.52, 4.44) |
| Markers of HBV | 0.65 (0.27, 1.59) |
| HCV Genotype G1 | 1.58 (0.36, 6.90) |
| HCV RNA (IU/mL): ≥106 | 0.72 (0.30, 1.75) |
| Interferon Treatment | 1.78 (0.41, 7.67) |
| Audit Score ≥8 | 1.72 (0.48, 6.08) |
| Concurrent IDU | 0.71 (0.27, 1.91) |
| Over 25 years as IDU | 0.90 (0.38, 2.12) |
| Initiation of ART | 1.92 (0.45, 8.33) |
| Enrollment during 2000–2001 | 2.37 (0.87, 6.46) |
| Variable . | Unadjusted HR (95% CI) . |
|---|---|
| Age >45 vs ≤45 years | 1.57 (0.68, 3.59) |
| Male vs female | 2.33 (0.80, 6.84) |
| Race/Ethnicity | |
| Black non-Hispanic | 1.57 (0.51, 4.82) |
| Hispanic | 1.62 (0.47, 5.54) |
| White non-Hispanic | Referent |
| History of diabetes | 1.52 (0.52, 4.44) |
| Markers of HBV | 0.65 (0.27, 1.59) |
| HCV Genotype G1 | 1.58 (0.36, 6.90) |
| HCV RNA (IU/mL): ≥106 | 0.72 (0.30, 1.75) |
| Interferon Treatment | 1.78 (0.41, 7.67) |
| Audit Score ≥8 | 1.72 (0.48, 6.08) |
| Concurrent IDU | 0.71 (0.27, 1.91) |
| Over 25 years as IDU | 0.90 (0.38, 2.12) |
| Initiation of ART | 1.92 (0.45, 8.33) |
| Enrollment during 2000–2001 | 2.37 (0.87, 6.46) |
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders identification test; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; IDU, injecting drug use.
Unadjusted Relative Hazards of Liver Disease Progression Events for Baseline Covariates
| Variable . | Unadjusted HR (95% CI) . |
|---|---|
| Age >45 vs ≤45 years | 1.57 (0.68, 3.59) |
| Male vs female | 2.33 (0.80, 6.84) |
| Race/Ethnicity | |
| Black non-Hispanic | 1.57 (0.51, 4.82) |
| Hispanic | 1.62 (0.47, 5.54) |
| White non-Hispanic | Referent |
| History of diabetes | 1.52 (0.52, 4.44) |
| Markers of HBV | 0.65 (0.27, 1.59) |
| HCV Genotype G1 | 1.58 (0.36, 6.90) |
| HCV RNA (IU/mL): ≥106 | 0.72 (0.30, 1.75) |
| Interferon Treatment | 1.78 (0.41, 7.67) |
| Audit Score ≥8 | 1.72 (0.48, 6.08) |
| Concurrent IDU | 0.71 (0.27, 1.91) |
| Over 25 years as IDU | 0.90 (0.38, 2.12) |
| Initiation of ART | 1.92 (0.45, 8.33) |
| Enrollment during 2000–2001 | 2.37 (0.87, 6.46) |
| Variable . | Unadjusted HR (95% CI) . |
|---|---|
| Age >45 vs ≤45 years | 1.57 (0.68, 3.59) |
| Male vs female | 2.33 (0.80, 6.84) |
| Race/Ethnicity | |
| Black non-Hispanic | 1.57 (0.51, 4.82) |
| Hispanic | 1.62 (0.47, 5.54) |
| White non-Hispanic | Referent |
| History of diabetes | 1.52 (0.52, 4.44) |
| Markers of HBV | 0.65 (0.27, 1.59) |
| HCV Genotype G1 | 1.58 (0.36, 6.90) |
| HCV RNA (IU/mL): ≥106 | 0.72 (0.30, 1.75) |
| Interferon Treatment | 1.78 (0.41, 7.67) |
| Audit Score ≥8 | 1.72 (0.48, 6.08) |
| Concurrent IDU | 0.71 (0.27, 1.91) |
| Over 25 years as IDU | 0.90 (0.38, 2.12) |
| Initiation of ART | 1.92 (0.45, 8.33) |
| Enrollment during 2000–2001 | 2.37 (0.87, 6.46) |
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders identification test; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; IDU, injecting drug use.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
